• EdU Imaging Kits (HF488): Reliable Proliferation Data

  2026-09-28

  This scenario-driven guide explains how EdU Imaging Kits (HF488), SKU K2240, support reproducible DNA synthesis measurement in fluorescence microscopy and flow cytometry. It connects assay design, protocol control, data interpretation, and vendor selection to practical laboratory decisions.

• Rotavirus Infection Suppresses Nrf2 Redox Defense

  2026-09-28

  The study reports a biphasic Nrf2 response to rotavirus: an early, redox-sensitive increase gives way to sustained loss of Nrf2 and several antioxidant target genes. Its experiments distinguish this later decline from canonical Keap1/Cul3-mediated turnover and link it to proteasome activity and increased K48-linked ubiquitination.

• Thiothixene: Workflows for Efferocytosis Research

  2026-09-27

  Thiothixene is a typical antipsychotic agent with a distinct research application: enhancing macrophage clearance of apoptotic and lipid-laden cells. This guide translates its reported 2 μM in vitro use into a practical workflow, with experimental controls, handling guidance, and limits on interpreting the pharmacokinetic evidence.

• Nocodazole and the Tubulin Code: Smarter Assays

  2026-09-26

  Nocodazole is more than a mitotic blocker: used thoughtfully, this microtubule polymerization inhibitor can help separate microtubule dynamics from tubulin modification in cell-based experiments. Explore how recent findings on α-tubulin lactylation inform assay design, interpretation, and controls.

• OCT2 and MATE1 Inhibition by 5-HT3 Antiemetics

  2026-09-25

  George and colleagues compared five 5-HT3 antiemetics for inhibition of renal OCT2 and MATE1, identifying distinct potency profiles and measurable effects on cellular and transepithelial transport. The findings support further evaluation of transporter-mediated drug interactions, but the cell-based results do not by themselves establish a clinical interaction or its magnitude.

• hiPSC-Derived Platelets: An Optimized 2026 Protocol

  2026-09-25

  A 2026 study optimized human iPSC differentiation into megakaryocytes and functional platelets by adjusting embryoid-body input, medium composition, and small-molecule support. The reported protocol reached platelet production in 19 days, yielded 14.9 platelets per iPSC, and reduced estimated costs by 58.3% in the study’s comparison.

• Making TNBC Target Validation More Measurable

  2026-09-24

  A recent preclinical study positions the Lin28B–Let-7–PBK axis as a potential therapeutic vulnerability in triple-negative breast cancer. This article examines how sensitive immunoblotting can strengthen target-validation workflows, where evidence is promising but still preliminary, and how to interpret protein readouts alongside RNA and functional assays.

• Sodium Ascorbate: Cancer Assay Workflows

  2026-09-24

  Build a solvent-aware workflow for testing Sodium Ascorbate in ROS-linked cancer-cell assays, from controlled dosing to orthogonal cell-death readouts. The guide also separates established glioblastoma findings from a new ESCC immunotherapy biomarker study, helping researchers avoid unsupported cross-domain conclusions.

• GTP Solution for p21 mRNA Workflows

  2026-09-23

  Learn how a high-purity GTP stock can support in vitro transcription and quality-controlled p21 mRNA–LNP research. The workflow connects nucleotide handling to localized bladder cancer assays while clearly separating reagent use from therapeutic evidence.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-23

  This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in rats through nasal inflammation, Th1/Th2-related signaling, and intestinal microbial changes. Its main contribution is a multi-layer analysis linking improved symptoms and mucosal pathology with altered bacterial composition, higher short-chain fatty acids, and reduced IgE, IL-4, STAT5, STAT6, and GATA3 signals.

• Bafilomycin C1: From Lysosomes to Safer Screens

  2026-09-22

  A translational guide to using Bafilomycin C1 as a mechanistically interpretable V-ATPase perturbation in autophagy assays, high-content phenotypic screens, and iPSC-derived models.

• Anti-ROR1 Antibody Workflow Guide

  2026-09-22

  Build a connected workflow from recombinant ROR1 binding and cell-surface profiling to Wnt5a pathway perturbation. This guide also explains how to use the reference liver-injury study to strengthen orthogonal assay design without overstating cross-disease evidence.

• Palonosetron for Chemotherapy-Induced Nausea and Vomiting

  2026-09-21

  Ruhlmann and Herrstedt review why palonosetron may provide clinically useful advantages over earlier 5-HT3 receptor antagonists, linking prolonged receptor engagement with protection against acute and delayed chemotherapy-induced nausea and vomiting. The paper’s practical contribution is a critical comparison of pharmacology, preclinical emesis models, comparative trials, tolerability, and the limits of translating receptor-level differences into better patient outcomes.

• Polymyxin B: From Membrane Damage to Translation

  2026-09-21

  Polymyxin B sulfate is more than a membrane-active antibiotic: it is a translational research tool for connecting bacterial killing, immune signaling, and infection-model design. This article shows how to use it in Gram-negative bacterial infection research while interpreting dendritic cell, sepsis, bacteremia, and microbiome-immunotherapy findings without overstating clinical relevance.

• ERADECs: Hijacking ERAD to Degrade Membrane Proteins

  2026-09-20

  Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a small-molecule strategy that redirects endoplasmic reticulum-associated degradation toward transmembrane proteins. Desonide-based ERADECs produced SYVN1- and ERAD-dependent PD-L1 degradation, strong in vivo activity, and an initial extension to mutant HTT, while also defining important limits for translation.

8564 records 1/571 page Next 12345 下5页 Last page